Which has stronger valuation and earnings, FLNA or KTTA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A

Is FLNA or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Pasithea Therapeutics N/A -57.44% -53.61%

Does the media refer more to FLNA or KTTA?

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.30 beat Pasithea Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KTTA or RNXT?

In the previous week, RenovoRx had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for RenovoRx and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EXOZ or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 541.03%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is EXOZ or KTTA more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Pasithea Therapeutics N/A -57.44% -53.61%

Does the media refer more to EXOZ or KTTA?

In the previous week, eXoZymes and eXoZymes both had 1 articles in the media. eXoZymes' average media sentiment score of 0.85 beat Pasithea Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, KTTA or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is KTTA or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% Alterity Therapeutics N/A N/A N/A

Does the media favor KTTA or ATHE?

In the previous week, Alterity Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.39 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BHST or KTTA?

In the previous week, BioHarvest Sciences had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for BioHarvest Sciences and 1 mentions for Pasithea Therapeutics. BioHarvest Sciences' average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioHarvest Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pasithea Therapeutics (KTTA) Competitors

$0.47 +0.01 (+1.74%)

As of 12:54 PM Eastern

Compare

KTTA vs. FLNA, RNXT, EXOZ, ATHE, and BHST

Should you buy Pasithea Therapeutics stock or one of its competitors? MarketBeat compares Pasithea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pasithea Therapeutics include Cassava Sciences (FLNA), RenovoRx (RNXT), eXoZymes (EXOZ), Alterity Therapeutics (ATHE), and BioHarvest Sciences (BHST).

How does Pasithea Therapeutics compare to Cassava Sciences?

Cassava Sciences (NASDAQ:FLNA) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

In the previous week, Cassava Sciences and Cassava Sciences both had 1 articles in the media. Cassava Sciences' average media sentiment score of 1.30 beat Pasithea Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 414.40%. Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 541.03%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cassava Sciences has a beta of -0.7, meaning that its share price is 170% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Cassava Sciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Summary

Pasithea Therapeutics beats Cassava Sciences on 7 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to RenovoRx?

Pasithea Therapeutics (NASDAQ:KTTA) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, RenovoRx had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for RenovoRx and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 equaled RenovoRx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RenovoRx has higher revenue and earnings than Pasithea Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
RenovoRx	$1.12M	42.84	-$11.17M	-$0.33	N/A

Pasithea Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 541.03%. RenovoRx has a consensus price target of $8.50, suggesting a potential upside of 698.12%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Pasithea Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Comparatively, 9.4% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pasithea Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Pasithea Therapeutics' return on equity of -57.44% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats Pasithea Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

eXoZymes has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

eXoZymes has higher revenue and earnings than Pasithea Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	698.64	-$9.16M	-$1.14	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Pasithea Therapeutics' return on equity of -57.44% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 541.03%. Given Pasithea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pasithea Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, eXoZymes and eXoZymes both had 1 articles in the media. eXoZymes' average media sentiment score of 0.85 beat Pasithea Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.9% of Pasithea Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Pasithea Therapeutics beats eXoZymes on 8 of the 14 factors compared between the two stocks.

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

In the previous week, Alterity Therapeutics had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.39 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Alterity Therapeutics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Alterity Therapeutics	N/A	N/A	N/A

Pasithea Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 541.03%. Alterity Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 188.57%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Pasithea Therapeutics and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Pasithea Therapeutics compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Pasithea Therapeutics (NASDAQ:KTTA) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

BioHarvest Sciences has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

BioHarvest Sciences currently has a consensus target price of $10.00, indicating a potential upside of 330.11%. Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 541.03%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pasithea Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Pasithea Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. Pasithea Therapeutics' return on equity of -57.44% beat BioHarvest Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

BioHarvest Sciences has higher revenue and earnings than Pasithea Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	1.32	-$11.14M	-$0.59	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

23.9% of Pasithea Therapeutics shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioHarvest Sciences had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for BioHarvest Sciences and 1 mentions for Pasithea Therapeutics. BioHarvest Sciences' average media sentiment score of 0.00 equaled Pasithea Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioHarvest Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pasithea Therapeutics beats BioHarvest Sciences on 8 of the 14 factors compared between the two stocks.

Get Pasithea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KTTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KTTA vs. The Competition

Export

Metric	Pasithea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.67M	$3.60B	$6.89B	$12.94B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-0.23	7.43	280.56	25.55
Price / Sales	N/A	1,298.26	597.22	91.90
Price / Cash	N/A	103.44	72.11	49.40
Price / Book	0.20	17.29	13.01	6.10
Net Income	-$20.43M	-$12.52M	$3.49B	$348.05M
7 Day Performance	4.00%	4.15%	3.66%	4.87%
1 Month Performance	-14.88%	-4.95%	-2.40%	-2.01%
1 Year Performance	-32.76%	50.70%	74.00%	21.16%

Pasithea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KTTA Pasithea Therapeutics	2.9198 of 5 stars	$0.47 +1.7%	$3.00 +541.0%	-35.2%	$11.67M	N/A	N/A	3
FLNA Cassava Sciences	2.1172 of 5 stars	$0.87 -1.7%	$5.00 +475.0%	-56.5%	$42.75M	N/A	N/A	20	Positive News Earnings Report
RNXT RenovoRx	3.6526 of 5 stars	$0.90 -1.0%	$8.50 +846.4%	-14.0%	$40.88M	$1.12M	N/A	6	News Coverage Upcoming Earnings
EXOZ eXoZymes	0.4851 of 5 stars	$4.49 +2.0%	N/A	-53.5%	$40.53M	$70K	N/A	29	News Coverage
ATHE Alterity Therapeutics	2.9051 of 5 stars	$4.60 +0.5%	$13.00 +182.9%	-15.7%	$40.48M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KTTA) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. FLNA, RNXT, EXOZ, ATHE, and BHST

How does Pasithea Therapeutics compare to Cassava Sciences?

Summary

How does Pasithea Therapeutics compare to RenovoRx?

Summary

How does Pasithea Therapeutics compare to eXoZymes?

Summary

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Summary

How does Pasithea Therapeutics compare to BioHarvest Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pasithea Therapeutics (KTTA) Competitors

KTTA vs. FLNA, RNXT, EXOZ, ATHE, and BHST

How does Pasithea Therapeutics compare to Cassava Sciences?

Does the media refer more to FLNA or KTTA?

Do analysts rate FLNA or KTTA?

Do institutionals and insiders believe in FLNA or KTTA?

Which has more volatility and risk, FLNA or KTTA?

Is FLNA or KTTA more profitable?

Which has stronger valuation and earnings, FLNA or KTTA?

Summary

How does Pasithea Therapeutics compare to RenovoRx?

Does the media prefer KTTA or RNXT?

Which has preferable earnings & valuation, KTTA or RNXT?

Do analysts rate KTTA or RNXT?

Which has more risk and volatility, KTTA or RNXT?

Do insiders & institutionals hold more shares of KTTA or RNXT?

Is KTTA or RNXT more profitable?

Summary

How does Pasithea Therapeutics compare to eXoZymes?

Which has more volatility & risk, EXOZ or KTTA?

Which has preferable valuation & earnings, EXOZ or KTTA?

Is EXOZ or KTTA more profitable?

Do analysts recommend EXOZ or KTTA?

Does the media refer more to EXOZ or KTTA?

Do insiders & institutionals have more ownership in EXOZ or KTTA?

Summary

How does Pasithea Therapeutics compare to Alterity Therapeutics?

Do insiders and institutionals have more ownership in KTTA or ATHE?

Which has preferable earnings and valuation, KTTA or ATHE?

Does the media favor KTTA or ATHE?

Which has more volatility and risk, KTTA or ATHE?

Is KTTA or ATHE more profitable?

Do analysts recommend KTTA or ATHE?

Summary

How does Pasithea Therapeutics compare to BioHarvest Sciences?

Which has more risk & volatility, BHST or KTTA?

Do analysts rate BHST or KTTA?

Is BHST or KTTA more profitable?

Which has higher valuation and earnings, BHST or KTTA?

Do insiders and institutionals have more ownership in BHST or KTTA?

Does the media favor BHST or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KTTA vs. The Competition

Pasithea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools